Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06634719 · ClinicalTrials.gov registry record · NA

Juveena Hydrogel System Feasibility Study for Heavy Menstrual Bleeding (HMB)

A NA study of Heavy Menstrual Bleeding, sponsored by Rejoni.

Recruiting
Registry status
NA
Development phase
7
Enrollment target
4
Study locations

NCT06634719 is a NA study of Heavy Menstrual Bleeding that is actively recruiting participants, run by Rejoni. The registered enrollment target is 7 participants, below the 225-participant average among 9 other Heavy Menstrual Bleeding trials with a reported enrollment target (97% lower). The trial reports 4 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06634719, a NA study of Heavy Menstrual Bleeding, is actively recruiting participants, sponsored by Rejoni.

RECRUITING
Registry status
NA
Development phase
7 participants
Enrollment target
4
Study locations

Study Summary

This is a prospective, multicenter, single-arm interventional feasibility study to evaluate the safety and feasibility of the Juveena Hydrogel System for temporary control of heavy menstrual bleeding (HMB) in women with a history of chronic ovulatory HMB.

Conditions Studied

Interventions

  • DEVICE Juveena Hydrogel System

Study Locations (4)

Arizona

  • Arizona Gynecology Consultants - Phoenix

Arkansas

  • Applied Research Center of Arkansas - Little Rock

New Jersey

  • Rubino OB/GYN (Axia Women's Health) - West Orange

Ohio

  • Seven Hills Clinical Research Group, LLC - Cincinnati

Trial Details

FieldValue
Enrollment Target 7 participants
Start Date 2025-02-01
Est. Completion 2025-12-31
Phase NA

Sponsor

Rejoni

3 total trials

What the Registry Record Tells You About NCT06634719

The ClinicalTrials.gov registry entry for NCT06634719 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 225-participant average among 9 other Heavy Menstrual Bleeding trials with a reported enrollment target (97% lower). The listed sponsor is Rejoni, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Heavy Menstrual Bleeding appearing as the primary indexed condition, and to 1 intervention - of which Juveena Hydrogel System is the first listed.

NCT06634719 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Arizona, Arkansas, New Jersey.

Frequently Asked Questions

What is clinical trial NCT06634719 about?

NCT06634719 is a clinical study titled "Juveena Hydrogel System Feasibility Study for Heavy Menstrual Bleeding (HMB)". This is a prospective, multicenter, single-arm interventional feasibility study to evaluate the safety and feasibility of the Juveena Hydrogel System for temporary control of heavy menstrual bleeding (HMB) in women with a history of chronic ovulatory HMB.

What is the current status of trial NCT06634719?

This trial is currently recruiting. It is a NA study. The enrollment target is 7 participants. The study started on 2025-02-01. Estimated completion is 2025-12-31.

What conditions does trial NCT06634719 study?

This clinical trial studies the following conditions: Heavy Menstrual Bleeding.

What interventions are being tested in trial NCT06634719?

The interventions under investigation include: Juveena Hydrogel System (DEVICE).

Who is sponsoring clinical trial NCT06634719?

This trial is sponsored by Rejoni, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06634719 being conducted?

This trial has 4 study locations across Arizona, Arkansas, New Jersey, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Heavy Menstrual Bleeding

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.